Alto Neuroscience Backer Bets $22 Entry on 2027 Trial Catalysts

A retail investor holding ANRO at ~$22 cites $319.8M cash, a runway to 2030, and three clinical readouts due by mid-2027 as the core of a high-risk biotech bet.